NCT04406259

Atrioventricular Block and Cluster Headache (SEVA)

Atrioventricular Block and Cluster Headache

• Status: Active Not Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Centre Hospitalier Universitaire de Nice · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Verapamil is a calcium channel blocker widely used to treat cardiovascular diseases however it is also the first line treatment in the prevention of cluster headaches. In France, its prescription in that indication is based on compliance with the Temporary Recommendation for Use (RTU) that insists on the possible the cardiac side effects that can occur as the doses required for cluster headache are significantly higher than the doses used in cardiology.

Conditions

• Cluster Headache

Interventions

Type	Name	Description
DRUG	Verapamil	Patients in groupe A require verapamil initiation as a preventive treatment and patients in group B are patients already undergoing a verapamil treatment for their Cluster Headache. The doses of verapamil are increased for the patients in group A, after a clinical examination an electrocardiogram, and a blood test.

Timeline

• Start date: 2020-11-02
• Primary completion: 2025-09-05
• Completion: 2027-09-05
• First posted: 2020-05-28
• Last updated: 2025-12-02

Locations

2 sites across 1 country: France